XXXX inhibitors in clinical practice.

@entity1 @entity5735 @entity6 @entity15072 @entity4053 @entity12349 @entity1017 @entity12350 @entity74 @entity164 @entity413 @entity5445
@entity164 2 @entity6 is a @entity74 , with major consequences for @entity1 , society, and health care services. Good glycemic control is an important aspect of @entity6 management because it has a significant impact on @entity6 -related microvascular and possibly macrovascular complications. Based on our understanding of the pathogenesis of @entity6 , multiple pharmacological interventions have been developed in the past 60 years. Although effective, none have had a lasting effect on glycemic control because of the progressive nature of @entity164 2 @entity6 requiring combination therapies and insulin treatment. In addition, several pharmacologic interventions have undesirable side effects, including @entity4053 and @entity1017 . Drugs targeting the incretin pathway are the latest addition to the available antidiabetes agents. Incretin-based therapy is either delivered orally ( @entity5735 [ @entity5735 ]) inhibitors or injected subcutaneously ( @entity5445 [ @entity5445 ] mimetics and analogues). @entity5735 inhibitors are effective either as a single or combination therapy in lowering glycated hemoglobin, fasting and postprandial @entity413 levels, with a low incidence of @entity4053 and no @entity1017 . There are 3 @entity5735 inhibitors currently available ( @entity12350 , @entity15072 , and @entity12349 ), with more expected to be available in the future. In this article, we review the scientific background for incretin-based therapy and the available evidence regarding the role and efficacy of @entity5735 inhibitors in the treatment of @entity1 with @entity164 2 @entity6 .
